Ultragenyx Pharmaceutical logo

Ultragenyx Pharmaceutical Share Price Today

(NASDAQ: RARE)

Ultragenyx Pharmaceutical share price is $39.34 & ₹3,419.75 as on 15 Mar 2025, 2.30 'hrs' IST

$39.34

0.09

(0.23%)

Market is closed - opens 7 PM, 17 Mar 2025

View live Ultragenyx Pharmaceutical share price in Dollar and Rupees. Guide to invest in Ultragenyx Pharmaceutical stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Ultragenyx Pharmaceutical, along with analyst recommendations, forecasts, and comprehensive financials.

Ultragenyx Pharmaceutical share price movements

  • Today's Low: $39.05
    Today's High: $40.03

    Day's Volatility :2.45%

  • 52 Weeks Low: $37.02
    52 Weeks High: $60.37

    52 Weeks Volatility :38.68%

Ultragenyx Pharmaceutical (RARE) Returns

PeriodUltragenyx Pharmaceutical Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-13.55%
2.0%
0.0%
6 Months
-33.88%
-7.9%
0.0%
1 Year
-17.14%
-1.4%
0.0%
3 Years
-42.07%
10.8%
-8.9%

Ultragenyx Pharmaceutical (RARE) Key Statistics

in dollars & INR

Previous Close
$39.25
Open
$39.32
Today's High
$40.03
Today's Low
$39.05
Market Capitalization
$3.6B
Today's Volume
$427.3K
52 Week High
$60.37
52 Week Low
$37.02
Revenue TTM
$560.2M
EBITDA
$-500.4M
Earnings Per Share (EPS)
$-6.29
Profit Margin
-101.6%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-211.71%

How to invest in Ultragenyx Pharmaceutical Stock (RARE) from India?

It is very easy for Indian residents to invest directly in Ultragenyx Pharmaceutical from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ultragenyx Pharmaceutical stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ultragenyx Pharmaceutical or RARE on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ultragenyx Pharmaceutical or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ultragenyx Pharmaceutical shares which would translate to 0.022 fractional shares of Ultragenyx Pharmaceutical as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Ultragenyx Pharmaceutical, in just a few clicks!

Returns in Ultragenyx Pharmaceutical (RARE) for Indian investors in Rupees

The Ultragenyx Pharmaceutical stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Ultragenyx Pharmaceutical investment value today

Current value as on today

₹88,004

Returns

₹11,996

(-12%)

Returns from Ultragenyx Pharmaceutical Stock

₹16,952 (-16.95%)

Dollar Returns

₹4,956 (+4.96%)

Indian investors sentiment towards Ultragenyx Pharmaceutical (RARE)

100%

Period: Feb 12, 2025 to Mar 14, 2025. Change in 30 Days versus previous period

Search interest for Ultragenyx Pharmaceutical Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Ultragenyx Pharmaceutical

  • Vanguard Group Inc

    10.85%

  • BlackRock Inc

    7.07%

  • Sands Capital Management, LLC

    4.65%

  • State Street Corp

    2.94%

  • T. Rowe Price Associates, Inc.

    2.72%

  • Wellington Management Company LLP

    2.66%

Analyst Recommendation on Ultragenyx Pharmaceutical

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 27 Wall street analysts offering stock ratings for Ultragenyx Pharmaceutical(by analysts ranked 0 to 5 stars)

Based on 27 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
24
23
23
Hold
3
3
3
Sell
0
0
0

Analyst Forecast on Ultragenyx Pharmaceutical Stock (RARE)

What analysts predicted

Upside of 123.97%

Target:

$88.11

Current:

$39.34

Insights on Ultragenyx Pharmaceutical Stock (Ticker Symbol: RARE)

  • Price Movement

    In the last 7 days, RARE stock has moved up by 1.6%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 139.49M → 164.87M (in $), with an average increase of 15.4% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -133.51M → -133.38M (in $), with an average increase of 0.1% per quarter
  • RARE vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.8% return, outperforming this stock by 78.7%
  • RARE vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 59.3% return, outperforming this stock by 96.2%
  • Price to Sales

    ForRARE every $1 of sales, investors are willing to pay $6.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.7 for every $1 of sales.

Ultragenyx Pharmaceutical Technicals Summary

Sell

Neutral

Buy

Ultragenyx Pharmaceutical is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Ultragenyx Pharmaceutical (RARE) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ultragenyx Pharmaceutical Inc. logo
-9.62%
-33.88%
-17.14%
-42.07%
16.12%
Regeneron Pharmaceuticals, Inc. logo
2.52%
-40.97%
-29.43%
0.39%
54.39%
Beone Medicines Ltd logo
14.0%
29.59%
49.75%
38.86%
81.84%
Vertex Pharmaceuticals Incorporated logo
10.97%
2.76%
23.36%
102.37%
151.75%
Alnylam Pharmaceuticals, Inc. logo
-9.1%
-10.59%
61.95%
52.07%
145.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ultragenyx Pharmaceutical Inc. logo
NA
NA
-0.24
-5.43
-2.12
-0.22
NA
2.76
Regeneron Pharmaceuticals, Inc. logo
17.98
17.98
1.01
42.83
0.16
0.07
0.0
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.45
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.4
18.06
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.52
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ultragenyx Pharmaceutical Inc. logo
Buy
$3.6B
16.12%
NA
-101.6%
Regeneron Pharmaceuticals, Inc. logo
Buy
$75.4B
54.39%
17.98
31.07%
Beone Medicines Ltd logo
NA
$28.1B
81.84%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$127.2B
151.75%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
145.93%
NA
-12.37%

Ultragenyx Pharmaceutical Dividend announcements

  • Ultragenyx Pharmaceutical Earnings

    Ultragenyx Pharmaceutical’s price-to-earnings ratio stands at None

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
Organization
Ultragenyx Pharmaceutical
Employees
1294
CEO
Dr. Emil D. Kakkis M.D., Ph.D.
Industry
Health Technology

Management People of Ultragenyx Pharmaceutical

NameTitle
Dr. Emil D. Kakkis M.D., Ph.D.
Founder, President, CEO & Director
Mr. Howard Horn
Executive VP of Corporate Strategy & CFO
Ms. Karah Herdman Parschauer J.D.
Chief Legal Officer & Executive VP of Corporate Affairs
Mr. John Richard Pinion II
Chief Quality Operations Officer & Executive VP of Translational Sciences
Mr. Erik Harris M.B.A.
Executive VP & Chief Commercial Officer
Mr. Theodore A. Huizenga
Senior VP, Corporate Controller & Principal Accounting Officer
Mr. Ernie W. Meyer
Chief Human Resources Officer & Executive VP
Mr. Thomas R. Kassberg
Chief Business Officer & Executive VP
Mr. Vimal Srivastava
Senior Vice President of Business Development & Alliance Management
Mr. Dennis Karl Huang
Chief Technical Operations Officer and Executive VP of Gene Therapy Research & Development

Important FAQs about investing in RARE Stock from India :

What is Ultragenyx Pharmaceutical share price today?

Ultragenyx Pharmaceutical share price today stands at $39.34, Open: $39.32 ; Previous Close: $39.25 ; High: $40.03 ; Low: $39.05 ; 52 Week High: $60.37 ; 52 Week Low: $37.02.

The stock opens at $39.32, after a previous close of $39.25. The stock reached a daily high of $40.03 and a low of $39.05, with a 52-week high of $60.37 and a 52-week low of $37.02.

Can Indians buy Ultragenyx Pharmaceutical shares?

Yes, Indians can invest in the Ultragenyx Pharmaceutical (RARE) from India.

With INDmoney, you can buy Ultragenyx Pharmaceutical at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Ultragenyx Pharmaceutical at zero transaction cost.

How can I buy Ultragenyx Pharmaceutical shares from India?

It is very easy to buy Ultragenyx Pharmaceutical from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ultragenyx Pharmaceutical (RARE) be purchased?

Yes, you can buy fractional shares of Ultragenyx Pharmaceutical with INDmoney app.

What are the documents required to start investing in Ultragenyx Pharmaceutical stocks?

To start investing in Ultragenyx Pharmaceutical, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Ultragenyx Pharmaceutical Stock (RARE)?

Today’s highest price of Ultragenyx Pharmaceutical (RARE) is $40.03.

Today’s lowest price of Ultragenyx Pharmaceutical (RARE) is $39.05.

What is today's market capitalisation of Ultragenyx Pharmaceutical?

Today's market capitalisation of Ultragenyx Pharmaceutical RARE is 3.6B

What is the 52 Week High and Low Range of Ultragenyx Pharmaceutical Stock (RARE)?

  • 52 Week High

    $60.37

  • 52 Week Low

    $37.02

What are the historical returns of Ultragenyx Pharmaceutical (RARE)?

  • 1 Month Returns

    -9.62%

  • 3 Months Returns

    -33.88%

  • 1 Year Returns

    -17.14%

  • 5 Years Returns

    16.12%

Who is the Chief Executive Officer (CEO) of Ultragenyx Pharmaceutical ?

Dr. Emil D. Kakkis M.D., Ph.D. is the current Chief Executive Officer (CEO) of Ultragenyx Pharmaceutical.